Clinical trial NCT00504998: Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer
Official title: Phase I/II Evaluation of Safety and Efficacy of Rexin-G for Recurrent or Metastatic Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Pancreatic Cancer
Keywords: Pancreatic cancer
Rexin-G
Treatment
Lead sponsor: Epeius Biotechnologies
Sponsor class: INDUSTRY
First posted: 2007-07-20
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of the adaptive trial design is to determine the over-all safety of escalating doses of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol.

Detailed description: The clinical trial is a safety and efficacy study using escalating doses of Rexin-G that incorporates a Phase II component that will evaluate the efficacy of Rexin-G using an adaptive trial design. Each treatment cycle will be six weeks: four weeks of treatment and two weeks of rest. Unlike a standard Phase I protocol, eligible patients may have repeat cycles after the safety data and objective tumor response/s are recorded. Continued Rexin-G treatment will enable the targeted genetic medicine to catch up with tumor growth, halt disease progression, and reduce tumor burden. The treatment strategy is to achieve tumor control as quickly as safely possible. The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II/III pivotal trial.

Eligibility criteria: Inclusion Criteria:

1. Histologically or cytologically confirmed recurrent or metastatic pancreatic cancer that has failed gemcitabine and that is measurable.
2. Adequate hepatic function: Total bilirubin \< 2.0 mg/dL (upper limit included); AST/ALT \< 2x institutional norm; alkaline phosphatase \< 2.5x upper limit of institutional norm unless the patient has extensive bone metastases. Patients with elevated alkaline phosphatase due to extensive liver disease will be excluded from study; albumin \> 3.0 mg/dL. There must be no substantial ascites. PT and PTT must be within normal limits.
3. Performance status must be \< 1 (ECOG 0-1) with a life expectancy of at least 3 months.
4. Hemoglobin \> 9 gms%
5. Absolute granulocyte count \> 1000/uL, and platelet count \> 100,000/uL.
6. Serum creatinine of less than 1.5 mg%.
7. There must be no plans for the patient to receive further cancer therapy from the date of enrollment until the completion of the 6-week follow-up visit.
8. Accessibility of peripheral or central IV line
9. Age \> 10 years
10. Patients will be off chemotherapy for a minimum of 4 weeks prior to initiation of therapy and should have recovered to Grade 1 or less toxicity.
11. The ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Prior malignancy, except for non-melanoma skin cancer, stage 1 breast cancer, CIS of cervix from which the patient has been disease-free for 5 years.
2. Woman who are pregnant or nursing
3. Fertile patients unless they agree to use barrier contraception (condoms and spermicide jelly) during the vector infusion period and for six weeks after infusion. Male patients must agree to use barrier contraception.
4. Patients who are transfusion dependent (more than one transfusion per month)
5. Patients with medical, psychiatric, or social conditions that would compromise successful adherence to this protocol.
6. Patient who do not meet the inclusion criteria.

Primary outcomes:
measure: Clinical toxicity (DLT and MTD) as defined by patient performance status, toxicity assessment score, hematologic, and metabolic profiles.
timeFrame: 24
Secondary outcomes:
measure: To identify an objective tumor response to Rexin-G
timeFrame: 24 months
Other outcomes:
Locations:
city: San Marino
country: United States
facility: Epeius Clinical Research Unit
state: California
city: Santa Monica
country: United States
facility: Sarcoma Oncology Center
state: California
city: New York
country: United States
facility: Bruckner Oncology
state: New York
Study officials:
affiliation: Epeius Clinical Research Unit/Sarcoma Oncology Center
name: Sant P Chawla, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Bruckner Oncology
name: Howard W Bruckner, M.D.
role: PRINCIPAL_INVESTIGATOR
References: